The goal of this project is to develop small molecules that reverse the cellular phenotype of ARSACS into
a drug that would stop the progression of the disease and/or lead to clinical improvement. The project is
a multidisciplinary collaboration between Dr Bernard Brais’ (McGill Univ.) and Dr Michel Bouvier’s (IRIC,
Institute of Researcher in Immunology and Cancer, Univ. of Montreal) laboratories with the participation
of the High Throughput Screening (HTS) and Medicinal Chemistry core facilities at IRIC.
Duration: One year
Grant: $150,000
Contact
Dr.Michel Bouvier, Institute for Research in Immunology and Cancer (IRIC)
IRIC | Université de Montréal C.P. 6128, succursale Centre-ville, Montréal (Québec) H3C 3J7
Tel: (514)-343-6319 ; Email: michel.bouvier@umontreal.ca